全文获取类型
收费全文 | 2350054篇 |
免费 | 171620篇 |
国内免费 | 3334篇 |
专业分类
耳鼻咽喉 | 32049篇 |
儿科学 | 75891篇 |
妇产科学 | 62705篇 |
基础医学 | 348309篇 |
口腔科学 | 63635篇 |
临床医学 | 211347篇 |
内科学 | 457277篇 |
皮肤病学 | 51728篇 |
神经病学 | 185270篇 |
特种医学 | 88007篇 |
外国民族医学 | 489篇 |
外科学 | 353872篇 |
综合类 | 47517篇 |
现状与发展 | 12篇 |
一般理论 | 848篇 |
预防医学 | 182728篇 |
眼科学 | 54325篇 |
药学 | 175104篇 |
11篇 | |
中国医学 | 4575篇 |
肿瘤学 | 129309篇 |
出版年
2021年 | 18980篇 |
2019年 | 19536篇 |
2018年 | 27058篇 |
2017年 | 20359篇 |
2016年 | 22747篇 |
2015年 | 25643篇 |
2014年 | 36094篇 |
2013年 | 53968篇 |
2012年 | 74685篇 |
2011年 | 79410篇 |
2010年 | 47062篇 |
2009年 | 44568篇 |
2008年 | 74618篇 |
2007年 | 79486篇 |
2006年 | 80318篇 |
2005年 | 77798篇 |
2004年 | 74393篇 |
2003年 | 71706篇 |
2002年 | 69379篇 |
2001年 | 108746篇 |
2000年 | 111457篇 |
1999年 | 93506篇 |
1998年 | 26996篇 |
1997年 | 23664篇 |
1996年 | 24057篇 |
1995年 | 22720篇 |
1994年 | 20894篇 |
1993年 | 19716篇 |
1992年 | 72009篇 |
1991年 | 70074篇 |
1990年 | 68398篇 |
1989年 | 65674篇 |
1988年 | 60311篇 |
1987年 | 59132篇 |
1986年 | 55227篇 |
1985年 | 53013篇 |
1984年 | 39315篇 |
1983年 | 33396篇 |
1982年 | 19859篇 |
1979年 | 35866篇 |
1978年 | 25651篇 |
1977年 | 21230篇 |
1976年 | 20332篇 |
1975年 | 21816篇 |
1974年 | 26148篇 |
1973年 | 24802篇 |
1972年 | 23200篇 |
1971年 | 22037篇 |
1970年 | 20247篇 |
1969年 | 19315篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
993.
994.
995.
996.
A Nofal I Al-Makhzangy E Attwa A Nassar A Abdalmoati 《Journal of the European Academy of Dermatology and Venereology》2009,23(7):803-806
Background Psoriasis is a chronic disease characterized by abnormal epidermal proliferation, inflammation and angiogenesis. It has been reported that vascular endothelial growth factor (VEGF) is overexpressed in lesional psoriatic skin and its serum levels are significantly elevated in patients with moderate to severe disease.
Objective This study aims to evaluate the possible role of VEGF in the pathogenesis of psoriasis, and its significance as an indicator of disease severity and control.
Methods Thirty patients with moderate to severe psoriasis and 10 healthy controls were subjected to baseline evaluation of VEGF. Patients were divided into three groups according to the received treatment: psoralen plus ultraviolet A (PUVA) thrice weekly (group 1), acitretin 50 mg daily (group 2), and combined PUVA twice weekly and acitretin 25 mg daily (group 3).Treatment continued for 16 weeks or up to clinical cure. Every patient was subjected to severity evaluation by Psoriasis Area and Severity Index (PASI) and measurement of serum VEGF before and after treatment.
Results Mean serum levels of VEGF were significantly elevated in patients (327 ± 66.2 pg/mL) than control subjects (178 ± 83.4 pg/mL). A highly significant correlation was found between VEGF and PASI score, but not with other variables. The best clinical response, the least side-effects and the highest reduction of VEGF serum levels were achieved by the combined therapy.
Conclusion The present study supported the proposed role of VEGF in the pathogenesis of psoriasis, and suggested that it could serve as a good indicator of disease severity and control. 相似文献
Objective This study aims to evaluate the possible role of VEGF in the pathogenesis of psoriasis, and its significance as an indicator of disease severity and control.
Methods Thirty patients with moderate to severe psoriasis and 10 healthy controls were subjected to baseline evaluation of VEGF. Patients were divided into three groups according to the received treatment: psoralen plus ultraviolet A (PUVA) thrice weekly (group 1), acitretin 50 mg daily (group 2), and combined PUVA twice weekly and acitretin 25 mg daily (group 3).Treatment continued for 16 weeks or up to clinical cure. Every patient was subjected to severity evaluation by Psoriasis Area and Severity Index (PASI) and measurement of serum VEGF before and after treatment.
Results Mean serum levels of VEGF were significantly elevated in patients (327 ± 66.2 pg/mL) than control subjects (178 ± 83.4 pg/mL). A highly significant correlation was found between VEGF and PASI score, but not with other variables. The best clinical response, the least side-effects and the highest reduction of VEGF serum levels were achieved by the combined therapy.
Conclusion The present study supported the proposed role of VEGF in the pathogenesis of psoriasis, and suggested that it could serve as a good indicator of disease severity and control. 相似文献
997.
998.
999.
1000.
J.-P. Ortonne A. Taïeb A.D. Ormerod† D. Robertson‡ J. Foehl‡ R. Pedersen‡ C. Molta‡ B. Freundlich‡ 《The British journal of dermatology》2009,161(5):1190-1195
Background Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses.
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献